API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
http://www.takedaoncology.com/media/news-media/news-releases/Takeda-Announces-Phase-3-Trial-of-ALUNBRIG-brigatinib-Met-Pr-10146/Print
http://www.pharmatimes.com/news/alunbrig_scores_nice_backing_for_alk_lung_cancer_1359892
http://www.pharmafile.com/news/566013/nice-authorises-takedas-alunbrig-alk-positive-advanced-non-small-cell-lung-cancer
https://www.pharmiweb.com/press-release/2020-12-10/alunbrig-brigatinib-now-available-on-the-nhs-in-england-wales-and-northern-ireland-for-adults-with-alk-positive-advanced-non-small-cell-lung-cancer
http://www.pharmatimes.com/news/new_us_approval_for_takedas_alunbrig_1340874
https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line
http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936
https://www.raps.org/news-and-articles/news-articles/2020/2/chmp-recommends-one-new-drug-begins-review-of-ind
https://www.businesswire.com/news/home/20200224005128/en/Takeda-Announces-U.S.-FDA-Grants-Priority-Review/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.reuters.com/article/us-takeda-pharma-alunbrig/takeda-says-cancer-drug-alunbrig-shows-longer-benefit-vs-crizotinib-idUSKBN1XX02D
https://www.fiercepharma.com/marketing/takeda-eyes-alunbrig-earlier-lung-cancer-use-as-2-year-data-trounce-pfizer-s-xalkori
http://www.pharmafile.com/news/519468/european-approval-takedas-alunbrig-alk-advanced-non-small-cell-lung-cancer
https://www.ema.europa.eu/documents/product-information/alunbrig-epar-product-information_en.pdf
https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/
https://www.businesswire.com/news/home/20181019005217/en/Takeda-Present-Results-Phase-3-ALTA-1L-Trial
http://www.pharmatimes.com/news/preliminary_nice_no_for_takedas_alunbrig_1254340
https://www.fiercebiotech.com/biotech/f-prime-atlas-lead-cancer-startup-akrevia-to-30m-a-round
https://www.fiercepharma.com/marketing/takeda-alk-drug-alunbrig-trounces-pfizer-s-xalkori-bid-for-earlier-use
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018
https://www.raps.org/news-and-articles/news-articles/2018/9/chmp-backs-13-new-medicines-maintains-negative-op?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2021%20September
https://health.economictimes.indiatimes.com/news/pharma/takeda-lung-cancer-drug-gets-european-panel-nod/65901196
https://www.businesswire.com/news/home/20180725005065/en/Takeda-Announces-Phase-3-Trial-ALUNBRIG%C2%AE-brigatinib
https://www.biospectrumasia.com/news/39/11380/takeda-announces-phase-iii-trial-of-alunbrig-for-lung-cancer.html
https://endpts.com/takeda-rd-team-rings-the-blockbuster-bell-with-key-phiii-success-in-frontline-lung-cancer/
https://www.fiercepharma.com/pharma/asco-soundbites-vol-2-our-favorite-weekend-convo-snippets-from-execs-around-industry
https://www.businesswire.com/news/home/20180517006004/en/Takeda-Highlight-Broad-Oncology-Portfolio-Pipeline-Data
http://www.pmlive.com/pharma_news/pfizer_files_third-gen_alk_inhibitor_for_lung_cancer_1221723